Carlo Chizzolini

List of Publications by Year
in descending order

66	4,409	109321 35	118850 62
papers	citations	h-index	g-index

97	97	97	5591
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CCR5 is characteristic of Th1 lymphocytes. Nature, 1998, 391, 344-345.	27.8	886
2	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.9	410
3	Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood, 2008, 112, 3696-3703.	1.4	212
4	Activation of the aryl hydrocarbon receptor reveals distinct requirements for ILâ€22 and ILâ€17 production by human T helper cells. European Journal of Immunology, 2010, 40, 2450-2459.	2.9	166
5	CD4+ CD8+ double positive (DP) T cells in health and disease. Autoimmunity Reviews, 2004, 3, 215-220.	5.8	161
6	Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Research and Therapy, 2011, 13, R166.	3.5	148
7	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis and Rheumatism, 2002, 46, 1602-1613.	6.7	137
8	Fibrosis and immune dysregulation in systemic sclerosis. Autoimmunity Reviews, 2011, 10, 276-281.	5.8	130
9	Presence of CD4+CD8+ doubleâ€positive T cells with very high interleukinâ€4 production potential in lesional skin of patients with systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 3459-3467.	6.7	127
10	Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor Î±. Arthritis and Rheumatism, 2003, 48, 2593-2604.	6.7	98
11	Human Th1 cells preferentially induce interleukin (IL)-1Î² while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. European Journal of Immunology, 1997, 27, 171-177.	2.9	92
12	Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of tollâ€like receptor 4. Arthritis and Rheumatism, 2008, 58, 3913-3923.	6.7	90
13	CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-Î± production in systemic sclerosis. Nature Communications, 2019, 10, 1731.	12.8	90
14	Interleukinâ€17A+ Cell Counts Are Increased in Systemic Sclerosis Skin and Their Number Is Inversely Correlated With the Extent of Skin Involvement. Arthritis and Rheumatism, 2013, 65, 1347-1356.	6.7	85
15	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis and Rheumatology, 2021, 73, 1073-1085.	5.6	81
16	Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Research and Therapy, 2013, 15, R151.	3.5	74
17	Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis. Journal of Investigative Dermatology, 2016, 136, 1970-1980.	0.7	73
18	Th2 Cell Membrane Factors in Association with IL-4 Enhance Matrix Metalloproteinase-1 (MMP-1) While Decreasing MMP-9 Production by Granulocyte-Macrophage Colony-Stimulating Factor-Differentiated Human Monocytes. Journal of Immunology, 2000, 164, 5952-5960.	0.8	72

#	Article	IF	Citations
19	Interplay Between Keratinocytes and Fibroblasts: A Systematic Review Providing a New Angle for Understanding Skin Fibrotic Disorders. Frontiers in Immunology, 2020, 11, 648.	4.8	72
20	Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: Different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis and Rheumatism, 1998, 41, 2039-2047.	6.7	67
21	A new molecular classification to drive precision treatment strategies in primary SjÃ¶grenâ€™s syndrome. Nature Communications, 2021, 12, 3523.	12.8	67
22	T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Current Opinion in Rheumatology, 2008, 20, 707-712.	4.3	58
23	Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. Journal of the American Academy of Dermatology, 2020, 82, 317-325.	1.2	52
24	Is there a role for IL-17 in the pathogenesis of systemic sclerosis?. Immunology Letters, 2018, 195, 61-67.	2.5	50
25	IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Annals of the Rheumatic Diseases, 2016, 75, 1697-1705.	0.9	48
26	Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1. Frontiers in Immunology, 2018, 9, 1865.	4.8	48
27	T cell abnormalities in systemic sclerosis with a focus on Th17 cells. European Cytokine Network, 2012, 23, 128-139.	2.0	45
28	Current Concepts on the Pathogenesis of Systemic Sclerosis. Clinical Reviews in Allergy and Immunology, 2023, 64, 262-283.	6.5	45
29	Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Annals of Medicine, 2007, 39, 42-53.	3.8	43
30	Impact of disease activity on health-related quality of life in systemic lupus erythematosus â€“ a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunology, 2017, 18, 17.	2.2	42
31	In Vivo Dioxin Favors Interleukin-22 Production by Human CD4+ T Cells in an Aryl Hydrocarbon Receptor (AhR)-Dependent Manner. PLoS ONE, 2011, 6, e18741.	2.5	41
32	Prostaglandin I2analogues enhance already exuberant Th17 cell responses in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 2044-2050.	0.9	39
33	High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. PLoS ONE, 2014, 9, e105008.	2.5	39
34	Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine, 2017, 84, 235-236.	1.6	39
35	The role of the acquired immune response in systemic sclerosis. Seminars in Immunopathology, 2015, 37, 519-528.	6.1	38
36	Prostaglandin E2: igniting the fire. Immunology and Cell Biology, 2009, 87, 510-511.	2.3	37

#	Article	IF	Citations
37	The Swiss Systemic lupus erythematosus Cohort Study (SSCS) â€“ cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Medical Weekly, 2014, 144, w13990.	1.6	31
38	Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?. Arthritis Research and Therapy, 2009, 11, 246.	3.5	30
39	TGFÎ² promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2021, 80, 1594-1603.	0.9	30
40	IL-17A Dissociates Inflammation from Fibrogenesis in Systemic Sclerosis. Journal of Investigative Dermatology, 2020, 140, 103-112.e8.	0.7	28
41	Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts. Arthritis Research and Therapy, 2006, 8, R10.	3.5	26
42	Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. International Journal of Molecular Sciences, 2020, 21, 5102.	4.1	26
43	Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site. Frontiers in Immunology, 2019, 10, 2619.	4.8	22
44	Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment. Frontiers in Pharmacology, 2021, 12, 633821.	3.5	21
45	T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Seminars in Immunopathology, 1999, 21, 431-450.	4.0	20
46	Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers. Rheumatology, 2020, 59, 3468-3478.	1.9	18
47	Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life. Quality of Life Research, 2017, 26, 1767-1775.	3.1	16
48	Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 2090.	4.8	16
49	Dysfunctional Keratinocytes Increase Dermal Inflammation in Systemic Sclerosis: Results From Studies Using Tissueâ€Engineered Scleroderma Epidermis. Arthritis and Rheumatology, 2021, 73, 1311-1317.	5.6	15
50	Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus. Nephrology Dialysis Transplantation, 2018, 33, 54-64.	0.7	12
51	Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. PLoS ONE, 2018, 13, e0188695.	2.5	12
52	T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Seminars in Immunopathology, 2000, 21, 431-450.	4.0	11
53	Serum interferon-Î± levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity. Annals of the Rheumatic Diseases, 2022, 81, 901-903.	0.9	11
54	Prevalence and Diseaseâ€Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. Arthritis Care and Research, 2018, 70, 1218-1227.	3.4	7

#	Article	IF	Citations
55	Interleukinâ€1Î²â€“Activated Microvascular Endothelial Cells Promote DCâ€SIGNâ€“Positive Alternatively Activated Macrophages as a Mechanism of Skin Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 1013-1026.	5.6	7
56	Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland. Memorias Do Instituto Oswaldo Cruz, 2018, 113, e170383.	1.6	6
57	Generation of Monoclonal Antibodies Specific for Native LL37 and Citrullinated LL37 That Discriminate the Two LL37 Forms in the Skin and Circulation of Cutaneous/Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients. Antibodies, 2020, 9, 14.	2.5	5
58	Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 761395.	4.8	5
59	IL-25 participates in keratinocyte-driven dermal matrix turnover and is reduced in systemic sclerosis epidermis. Rheumatology, 2022, 61, 4558-4569.	1.9	5
60	Introductory note to: Fibrosis year 2000. Seminars in Immunopathology, 2000, 21, 377-382.	4.0	4
61	T-cell subsets in scleroderma patients. Expert Review of Dermatology, 2010, 5, 403-415.	0.3	4
62	Matrix Metalloproteinases (MMPs) and Cytokines in Rheumatology. , 2017, , 123-155.		3
63	Inflammation and Immunity. , 2017, , 161-195.		2
64	Immunological Mechanisms. , 2012, , 165-189.		0
65	Basic Mechanisms Linking Inflammation and Fibrosis. Rare Diseases of the Immune System, 2017, , 17-31.	0.1	0
66	Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus. Genes, 2021, 12, 1268.	2.4	0